Blood advances, volume 4, issue 12, pages 2717-2722

Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.

Shukla Siddharth 1, 2
Jeong Ho-Chang 3
Sturgeon Christopher M 3, 4
PARKER ROY T 1, 2
Batista Luis Francisco Zirnberger 3, 4
1
 
Department of Biochemistry, University of Colorado Boulder, Boulder, CO;
2
 
Howard Hughes Medical Institute, Chevy Chase, MD; and
3
 
Department of Medicine and
4
 
Center of Regenerative Medicine, Washington University in St. Louis, St. Louis, MO
Publication typeJournal Article
Publication date2020-06-19
Journal: Blood advances
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor7.5
ISSN24739537
Hematology
Abstract

Dyskeratosis congenita (DC) is a pediatric bone marrow failure syndrome caused by germline mutations in telomere biology genes. Mutations in DKC1 (the most commonly mutated gene in DC), the 3′ region of TERC, and poly(A)-specific ribonuclease (PARN) cause reduced levels of the telomerase RNA component (TERC) by reducing its stability and accelerating TERC degradation. We have previously shown that depleting wild-type DKC1 levels by RNA interference or expression of the disease-associated A353V mutation in the DKC1 gene leads to decay of TERC, modulated by 3′-end oligoadenylation by noncanonical poly(A) polymerase 5 (PAPD5) followed by 3′ to 5′ degradation by EXOSC10. Furthermore, the constitutive genetic silencing of PAPD5 is sufficient to rescue TERC levels, restore telomerase function, and elongate telomeres in DKC1_A353V mutant human embryonic stem cells (hESCs). Here, we tested a novel PAPD5/7 inhibitor (RG7834), which was originally discovered in screens against hepatitis B viral loads in hepatic cells. We found that treatment with RG7834 rescues TERC levels, restores correct telomerase localization in DKC1 and PARN-depleted cells, and is sufficient to elongate telomeres in DKC1_A353V hESCs. Finally, treatment with RG7834 significantly improved definitive hematopoietic potential from DKC1_A353V hESCs, indicating that the chemical inhibition of PAPD5 is a potential therapy for patients with DC and reduced TERC levels.

Citations by journals

1
2
Journal of Clinical Medicine
Journal of Clinical Medicine, 2, 8.33%
Journal of Clinical Medicine
2 publications, 8.33%
Blood
Blood, 2, 8.33%
Blood
2 publications, 8.33%
Biomedicines
Biomedicines, 1, 4.17%
Biomedicines
1 publication, 4.17%
Science
Science, 1, 4.17%
Science
1 publication, 4.17%
Frontiers in Pharmacology
Frontiers in Pharmacology, 1, 4.17%
Frontiers in Pharmacology
1 publication, 4.17%
Nature Reviews Genetics
Nature Reviews Genetics, 1, 4.17%
Nature Reviews Genetics
1 publication, 4.17%
npj Genomic Medicine
npj Genomic Medicine, 1, 4.17%
npj Genomic Medicine
1 publication, 4.17%
Trends in Molecular Medicine
Trends in Molecular Medicine, 1, 4.17%
Trends in Molecular Medicine
1 publication, 4.17%
Journal of Biological Chemistry
Journal of Biological Chemistry, 1, 4.17%
Journal of Biological Chemistry
1 publication, 4.17%
Environmental Toxicology and Pharmacology
Environmental Toxicology and Pharmacology, 1, 4.17%
Environmental Toxicology and Pharmacology
1 publication, 4.17%
FEBS Letters
FEBS Letters, 1, 4.17%
FEBS Letters
1 publication, 4.17%
Biochemistry and Cell Biology
Biochemistry and Cell Biology, 1, 4.17%
Biochemistry and Cell Biology
1 publication, 4.17%
Chemical Reviews
Chemical Reviews, 1, 4.17%
Chemical Reviews
1 publication, 4.17%
Expert Review of Hematology
Expert Review of Hematology, 1, 4.17%
Expert Review of Hematology
1 publication, 4.17%
Nucleic Acids Research
Nucleic Acids Research, 1, 4.17%
Nucleic Acids Research
1 publication, 4.17%
Journal of Cell Biology
Journal of Cell Biology, 1, 4.17%
Journal of Cell Biology
1 publication, 4.17%
RNA
RNA, 1, 4.17%
RNA
1 publication, 4.17%
Cell Reports
Cell Reports, 1, 4.17%
Cell Reports
1 publication, 4.17%
Biochemical Society Transactions
Biochemical Society Transactions, 1, 4.17%
Biochemical Society Transactions
1 publication, 4.17%
Food Frontiers
Food Frontiers, 1, 4.17%
Food Frontiers
1 publication, 4.17%
1
2

Citations by publishers

1
2
3
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 3, 12.5%
Multidisciplinary Digital Publishing Institute (MDPI)
3 publications, 12.5%
Elsevier
Elsevier, 3, 12.5%
Elsevier
3 publications, 12.5%
Springer Nature
Springer Nature, 2, 8.33%
Springer Nature
2 publications, 8.33%
Wiley
Wiley, 2, 8.33%
Wiley
2 publications, 8.33%
American Society of Hematology
American Society of Hematology, 2, 8.33%
American Society of Hematology
2 publications, 8.33%
American Association for the Advancement of Science (AAAS)
American Association for the Advancement of Science (AAAS), 1, 4.17%
American Association for the Advancement of Science (AAAS)
1 publication, 4.17%
Frontiers Media S.A.
Frontiers Media S.A., 1, 4.17%
Frontiers Media S.A.
1 publication, 4.17%
American Society for Biochemistry and Molecular Biology
American Society for Biochemistry and Molecular Biology, 1, 4.17%
American Society for Biochemistry and Molecular Biology
1 publication, 4.17%
Canadian Science Publishing
Canadian Science Publishing, 1, 4.17%
Canadian Science Publishing
1 publication, 4.17%
American Chemical Society (ACS)
American Chemical Society (ACS), 1, 4.17%
American Chemical Society (ACS)
1 publication, 4.17%
Taylor & Francis
Taylor & Francis, 1, 4.17%
Taylor & Francis
1 publication, 4.17%
Oxford University Press
Oxford University Press, 1, 4.17%
Oxford University Press
1 publication, 4.17%
Rockefeller University Press
Rockefeller University Press, 1, 4.17%
Rockefeller University Press
1 publication, 4.17%
Cold Spring Harbor Laboratory
Cold Spring Harbor Laboratory, 1, 4.17%
Cold Spring Harbor Laboratory
1 publication, 4.17%
Portland Press
Portland Press, 1, 4.17%
Portland Press
1 publication, 4.17%
1
2
3
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Shukla S. et al. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita. // Blood advances. 2020. Vol. 4. No. 12. pp. 2717-2722.
GOST all authors (up to 50) Copy
Shukla S., Jeong H., Sturgeon C. M., PARKER R. T., Batista L. F. Z. Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita. // Blood advances. 2020. Vol. 4. No. 12. pp. 2717-2722.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1182/bloodadvances.2020001848
UR - https://doi.org/10.1182%2Fbloodadvances.2020001848
TI - Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.
T2 - Blood advances
AU - Shukla, Siddharth
AU - Jeong, Ho-Chang
AU - Sturgeon, Christopher M
AU - PARKER, ROY T
AU - Batista, Luis Francisco Zirnberger
PY - 2020
DA - 2020/06/19 00:00:00
PB - American Society of Hematology
SP - 2717-2722
IS - 12
VL - 4
PMID - 32559291
SN - 2473-9537
ER -
BibTex |
Cite this
BibTex Copy
@article{2020_Shukla,
author = {Siddharth Shukla and Ho-Chang Jeong and Christopher M Sturgeon and ROY T PARKER and Luis Francisco Zirnberger Batista},
title = {Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita.},
journal = {Blood advances},
year = {2020},
volume = {4},
publisher = {American Society of Hematology},
month = {jun},
url = {https://doi.org/10.1182%2Fbloodadvances.2020001848},
number = {12},
pages = {2717--2722},
doi = {10.1182/bloodadvances.2020001848}
}
MLA
Cite this
MLA Copy
Shukla, Siddharth, et al. “Chemical inhibition of PAPD5/7 rescues telomerase function and hematopoiesis in dyskeratosis congenita..” Blood advances, vol. 4, no. 12, Jun. 2020, pp. 2717-2722. https://doi.org/10.1182%2Fbloodadvances.2020001848.
Found error?